Jones Financial Companies’s NeuroSense Therapeutics NRSN Stock Holding History

Jones Financial Companies’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$731	Hold	1,000	–	–	﹤0.01%	4427
2025 Q4	$769	Hold	1,000	–	–	﹤0.01%	4076
2025 Q3	$1.24K	Sell	1,000 -9,919	-91%	-$14.5K	﹤0.01%	3843
2025 Q2	$20.7K	Buy	+10,919	New	+$15.8K	﹤0.01%	2574

Other funds holding NRSN

YAG

Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jones Financial Companies's NRSN Position: Q1 2026 in Review

Jones Financial Companies held its NeuroSense Therapeutics (NRSN) position steady in Q1 2026 at 1,000 shares worth $731. The position accounts for ﹤0.01% of the portfolio, ranked #4427.

Jones Financial Companies first reported a position in NRSN in Q2 2025 and has held it in 4 quarters since. The position peaked at $20.7K in Q2 2025. 13 funds tracked by Wall St. Rank hold NRSN as of Q1 2026.

Jones Financial Companies held 1,000 shares of NeuroSense Therapeutics worth $731 as of Q1 2026.
Jones Financial Companies left its NeuroSense Therapeutics share count unchanged in Q1 2026.
NeuroSense Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #4427 holding.
Jones Financial Companies first reported a position in NeuroSense Therapeutics in Q2 2025 and has held it in 4 quarters since.
Jones Financial Companies's NeuroSense Therapeutics position peaked at $20.7K in Q2 2025.
13 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.